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Chronic	myelogenous	leukemia	(CML)	results	from	a	chromosomal	translocation	in	hematopoietic	stem	or	
early	progenitor	cells	that	gives	rise	to	the	oncogenic	BCR/ABL	fusion	protein.	Clinically,	CML	has	a	chronic	
phase	that	eventually	evolves	into	an	accelerated	stage	and	blast	crisis.	A	CML-specific	immune	response	is	
thought	to	contribute	to	the	control	of	disease.	Whether	the	immune	system	can	also	promote	disease	progres-
sion	is	not	known.	In	the	present	study,	we	investigated	the	possibility	that	the	TNF	receptor	family	member	
CD27	is	present	on	leukemia	stem	cells	(LSCs)	and	mediates	effects	of	the	immune	system	on	CML.	In	a	mouse	
model	of	CML,	BCR/ABL+	LSCs	and	leukemia	progenitor	cells	were	found	to	express	CD27.	Binding	of	CD27	
by	its	ligand,	CD70,	increased	expression	of	Wnt	target	genes	in	LSCs	by	enhancing	nuclear	localization	of	
active	β-catenin	and	TRAF2-	and	NCK-interacting	kinase	(TNIK).	This	resulted	in	increased	proliferation	and	
differentiation	of	LSCs.	Blocking	CD27	signaling	in	LSCs	delayed	disease	progression	and	prolonged	survival.	
Furthermore,	CD27	was	expressed	on	CML	stem/progenitor	cells	in	the	bone	marrow	of	CML	patients,	and	
CD27	signaling	promoted	growth	of	BCR/ABL+	human	leukemia	cells	by	activating	the	Wnt	pathway.	Since	
expression	of	CD70	is	limited	to	activated	lymphocytes	and	dendritic	cells,	our	results	reveal	a	mechanism	
by	which	adaptive	immunity	contributes	to	leukemia	progression.	In	addition,	targeting	CD27	on	LSCs	may	
represent	an	attractive	therapeutic	approach	to	blocking	the	Wnt/β-catenin	pathway	in	CML.
Introduction
Chronic myelogenous leukemia (CML) is associated with the Phil-
adelphia (Ph′) chromosome, a reciprocal translocation between 
chromosomes 9 and 22 [t(9;22)(q34.1;q11.21)] (1). Ph′ leads to 
the formation of the oncogenic BCR/ABL fusion protein, a con-
stitutively active tyrosine kinase that is necessary and sufficient for 
malignant transformation (2). The BCR/ABL translocation arises 
in hematopoietic stem or early progenitor cells known as leukemia 
stem cells (LSCs) (3). Clinically, CML has a chronic phase character-
ized by dysregulated production and accumulation of mature gran-
ulocytes and eventually evolves into the accelerated stage and blast 
crisis through acquisition of further genetic abnormalities (4).
Clinical and experimental evidence suggests that CML elic-
its leukemia-specific immunity that contributes to the control 
of the disease. Cytotoxic CD8+ T lymphocytes (CTLs) directed 
against leukemia antigens were detected in the blood of CML 
patients (5). Several proteins may potentially act as leukemia-
specific antigens for T cells, including BCR/ABL, Wilms tumor 
1 protein (WT1), proteinase 3 (Pr3), and others (6). Similarly, 
CML-suppressive CD4+ T cell clones, NK cells, and NKT cells 
were reported (7, 8). In contrast, we recently showed that PD-1/ 
PD-L1 interaction and an impaired maturation of BCR/ABL-
expressing DCs reduced the efficacy of the CTL response against 
CML (9, 10). Therefore, an activated immune system coexists 
over a prolonged time period with CML.
CD27 is a member of the TNF receptor family, which includes 
death domain–containing (DD-containing) proapoptotic receptors 
(TNF-R1, CD95/Fas, APO-3, TRAIL-R1/2) as well as receptors that 
control gene regulation, induce proliferation, and promote survival. 
These latter receptors have cytoplasmic residues that are bound 
by TNF receptor–associated factors (TRAFs) and include CD27, 
CD30, CD40, CD134/OX-40, and many others (11). The cytoplas-
mic domain of CD27 binds TRAF2, which signals downstream via 
MAP3K family proteins, leading to IκB degradation and NF-κB acti-
vation (12). TRAF2 can also activate JNK family members, bind to 
the inhibitor of apoptosis proteins (IAPs) and lead to upregulation 
of Bcl-XL, an important antiapoptotic Bcl-2–like molecule (13, 14).
CD27 is expressed by subsets of T, B, and NK cells, and its role 
in the expansion and differentiation of effector T cells has been 
studied in detail (15). However, CD27 is also expressed on HSCs in 
BM (16), and CD27 signaling on HSCs and early BM progenitors 
provides a negative feedback signal toward leukocyte, especially 
B cell, differentiation (17).
The unique ligand of CD27 is the type II transmembrane glyco-
protein CD70. CD70 expression is tightly controlled, and CD70 is 
only transiently expressed by mature DCs and activated lympho-
cytes during inflammatory processes (18). Persistent or prolonged 
expression of CD70 is found in chronic viral infections, auto-
immune disorders, and some solid tumors and lymphomas (19).
Given the indications for an activated immune system in CML 
and the documented expression of CD27 on normal HSCs, 
we sought to analyze the expression of CD27 on LSCs with the 
aim of defining its function in leukemia. We used a retroviral 
transduction and transplantation model of BCR/ABL-induced 
CML-like disease in mice. CD27 was expressed by LSCs and 
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leukemia progenitors, and the CD70-CD27 interaction promoted 
LSC proliferation and CML disease progression. Gene expression 
analysis and immunostainings of LSCs revealed that CD27 signal-
ing induced the transcription of target genes of the canonical Wnt 
signaling pathway by enhancing the nuclear localization of active 
β-catenin and TRAF2- and NCK-interacting kinase (TNIK). As a 
consequence, blocking CD70 by mAb treatment reduced disease 
progression and prolonged survival of CML mice. Comparable 
to our results in the murine CML model, CD27 was expressed on 
CD34+ cells in BM of CML patients, and CD27 signaling in the 
human BCR/ABL+ leukemia cell line SD-1 activated the Wnt path-
way and promoted cell proliferation.
Results
Leukemia stem and progenitor cells express CD27. CML was induced 
by retroviral transduction of C57BL/6 (BL/6) BM cells with BCR/
ABL-GFP, followed by transfer to irradiated (4.5 Gy) BL/6 recipi-
ent mice (WT CML) (9). HSCs and LSCs were defined as lineage-
negative (lin–), Sca-1+, and c-kithi (20); common myeloid progeni-
tors (CMPs) were defined as lin–, Sca-1–, c-kithi, CD16/32–, and 
CD34lo; and granulocyte-macrophage progenitors (GMPs) as lin–, 
Sca-1–, c-kithi, CD16/32+, and CD34hi (21). We first analyzed CD27 
expression on LSCs, leukemia CMPs and GMPs, and differentiated 
granulocytes 20 days after transplantation. At this time point, WT 
CML mice had 62.8% ± 1.5% BCR/ABL-GFP+ Ly6-G+ granulocytes 
(of total granulocytes) in the peripheral blood. As a control, CD27 
expression was similarly assessed on HSCs, CMPs, and GMPs of 
naive BL/6 mice. CD27 surface expression was detected by FACS 
on HSCs (93.2% ± 1.2%) and, interestingly, also on CMPs (59.9% 
± 4.1%) and GMPs (87.0% ± 2.1%) (Figure 1A). In WT CML mice, 
CD27 was expressed on LSCs (32.8% ± 3.3%), leukemia CMPs 
(10.4% ± 2.7%), and leukemia GMPs (30.5% ± 5.5%) (Figure 1B). 
Mature granulocytes in the blood of naive BL/6 control mice and 
malignant granulocytes in WT CML mice did not express CD27 
(Figure 1C). Thus, although CD27 is expressed on normal HSCs, 
CMPs and GMPs, and on their malignant counterparts, the frac-
tion that expresses CD27 is substantially smaller in LSCs and 
malignant progenitors.
During immune activation, CD27 is shed from the cellular mem-
brane after being triggered by its ligand, CD70 (12). To determine 
whether the reduced expression of CD27 by LSCs is due to liga-
tion and shedding, we treated WT CML mice with CD70-blocking 
mAb FR70 or control IgG from rat serum. Blocking CD70-CD27 
interactions in WT CML mice resulted in upregulation of CD27 
expression on LSCs (Figure 1, D and E). In contrast, FR70 treat-
ment of naive BL/6 mice did not increase CD27 expression on 
HSCs (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI45977DS1).
The CD27 ligand CD70 is only transiently expressed on activat-
ed lymphocytes and dendritic cells during immune activation (12). 
In the BM of CML mice, CD70 mRNA expression was detectable 
mainly in CD3+ T cells and at lower levels in CD11c+ dendritic cells 
and CD19+ B cells. In contrast, BCR/ABL-GFP+ leukemia cells did 
not express significant amounts of CD70 (Figure 1F). Therefore, 
CD27 is expressed on LSCs and ligated by CD70 expressed on BM-
infiltrating immune cells.
CD27 signaling promotes CML progression. To analyze the role of 
CD27 signaling in CML development, we retrovirally transduced 
BM from BL/6 and Cd27–/– mice with BCR/ABL-GFP before 
transfer into irradiated (4.5 Gy) BL/6 recipient mice (Figure 2A). 
As shown before, at this reduced irradiation dose, the adaptive 
immune system, including CD8+ T cells, CD4+ T cells, and B cells, 
originates from the recipient mouse (10). Therefore, this experi-
mental setup allows generating CML from Cd27–/– BM cells in a 
host with a CD27-competent immune system (Cd27–/– CML). 
Thus, CD27 expression on lymphocytes was similar in Cd27–/– and 
WT CML mice (Supplemental Figure 2).
Even though the Cd27–/– mice are on a BL/6 background (22), 
we wanted to exclude small differences in the HSC compartment 
between both mouse strains. Subdifferentiation of LSK cells by 
FACS revealed no significant differences in absolute numbers of 
CD34–Flk2– LSK cells or CD34+Flk2– LSK cells between naive BL/6 
and Cd27–/– mice (Supplemental Figure 3).
BCR/ABL-GFP transduction efficacy was controlled in each 
experiment at the time point of transplantation. FACS analysis of 
Cd27–/– and BL/6 BM cells that were cultured in vitro revealed simi-
lar GFP expression and therefore similar retroviral transduction 
rates. Furthermore, transduced BL/6 and Cd27–/– BM cells formed 
equal numbers of BCR/ABL-GFP+ colonies in methylcellulose 
(Supplemental Figure 4). In addition, we controlled the clonal 
development of the CML 20 days after transplantation in spleens 
of WT and Cd27–/– CML mice. Real-time PCR of genomic DNA 
revealed comparable contents of human c-abl, indicating similar 
proviral integration of the BCR/ABL oncogene (Figure 2B). We 
also determined the expression of the oncogene BCR/ABL on the 
mRNA level in WT and Cd27–/– LSCs using quantitative real-time 
RT-PCR for human c-abl. We found no significant differences in 
oncogene expression in WT or Cd27–/– LSCs (Figure 2C). Similarly, 
MFI of BCR/ABL-GFP in lin– BM cells from WT and Cd27–/– CML 
mice were identical (Figure 2D). Thus, we conclude that WT and 
Cd27–/– LSCs and leukemia progenitors have a similar integration 
of human BCR/ABL in the genome and express similar amounts 
of BCR/ABL.
We next tested the homing capacity of retrovirally transduced 
BL/6 and Cd27–/– BM cells to the BM of BL/6 recipient mice in vivo. 
The numbers of lin– BCR/ABL-GFP+ cells, BCR/ABL-GFP+ LSCs, 
and BCR/ABL-GFP+ colony-forming cells isolated from BM 3 days 
after transfer were comparable (Supplemental Figure 5).
Blood smears, cytospins, and FACS analysis of granulocyte dif-
ferentiation markers revealed that granulocytes from WT and 
Cd27–/– CML mice were comparably differentiated and mature 
(Figure 2E and Supplemental Figure 6). Twelve days after trans-
plantation, WT and Cd27–/– CML mice had similar numbers of 
BCR/ABL-GFP+ granulocytes in the circulation, confirming simi-
lar engraftment of the malignant progenitor cells (Figure 2F). In 
contrast, progression of WT CML was significantly faster when 
compared with Cd27–/– CML, resulting in higher BCR/ABL-GFP+ 
granulocyte counts in the blood at later stages of the disease (Fig-
ure 2F and data not shown). WT CML mice all died because of 
leukemia within 40 days after transplantation (9, 10), whereas 
leukemia development was delayed in Cd27–/– CML animals and 
25% of them survived up to 80 days after transplantation with-
out overt leukemia, as analyzed by determination of peripheral 
blood granulocyte counts (Figure 2G and data not shown). CML 
mice died with classical symptoms of CML, such as high leuko-
cyte counts (Figure 2F), enlarged spleens (Supplemental Figure 
7A), pulmonary hemorrhage, and granulocyte infiltrations in 
different organs. The prolonged survival of Cd27–/– CML mice 
could not be attributed to differences in CD27 signaling to host 
T cells because BCR/ABL-GFP-transduced BL/6 BM cells induced 
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leukemias with similar kinetics in BL/6 and Cd27–/– hosts (Sup-
plemental Figure 8). Therefore, CD27 signaling on LSCs and 
CML progenitors promotes leukemia progression.
Characterization of LSCs and myelogenous leukemia progenitor cells. 
In a next step, we wanted to characterize LSCs and leukemia 
progenitors in WT and Cd27–/– CML animals in more detail. Fif-
teen days after transplantation, LSC numbers in WT and Cd27–/– 
CML mice were similar. However, 20 days after transplanta-
tion, LSC numbers in WT CML mice were significantly higher 
than in Cd27–/– CML mice (Figure 2H). Likewise, analysis of lin– 
Figure 1
CML stem and progenitor cells express CD27. (A) Expression of CD27 on naive BL/6 HSCs and myeloid lineage progenitors. One representa-
tive plot of 3 is shown. (B) Expression of CD27 on LSCs and myelogenous leukemia progenitors in WT CML. One representative plot of 5 is 
shown. (C) FACS analysis of CD27 on Ly6-G+ granulocytes in blood of naive BL/6 mice and BCR/ABL-GFP+ Ly6-G+ granulocytes in WT CML 
mice. 1 representative plot of 2–3 is shown. (D) WT CML animals were either treated with 300 μg IgG from rat serum (n = 10) or 300 μg FR70 
(n = 16) i.p., and CD27 was stained on LSCs after 12 hours. 1 representative histogram per group is shown. (E) CD27 expression on LSCs 
was calculated as MFI CD27 staining/MFI isotype staining for each sample. Pooled data from 3 independent experiments are shown. (F) CD70 
mRNA expression in cell subsets in BM cells pooled from WT CML mice. 1 representative of 2 experiments with n = 5–7 mice is shown. Data are 
displayed as mean ± SEM. Statistics: Student’s t test with Welch’s correction. Gray lines, isotype controls; black lines, CD27 stainings. MEPs, 
megakaryocyte-erythrocyte progenitors.
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BCR/ABL-GFP+ cells, lin– c-kithi BCR/ABL-GFP+ cells, BCR/ABL-
GFP+ CMPs, and GMPs revealed that CD27 signaling led to an 
increase in these myelogenous leukemia progenitor cell types 
(Figure 2I and Supplemental Figure 7, B–D).
CD27 signaling enhances proliferation and cell cycle progression of LSCs. 
CD27 signaling on lymphocytes enhances proliferation and induc-
es antiapoptotic molecules (12). So far, however, the question as 
to whether this also holds true for LSCs has not been addressed. 
Therefore, we compared proliferation and cell cycle progression of 
FACS-sorted LSCs from WT and Cd27–/– CML mice. Approximate-
ly 6%–7% of HSCs from naive BL/6 and Cd27–/– mice incorporated 
BrdU (Figure 3A). This is in agreement with published data indi-
cating that a small fraction of HSCs undergoes cell cycling (23). 
In contrast, BrdU incorporation in WT LSCs was approximately 
Figure 2
CD27 signaling promotes CML progression. (A) Experimental model. (B) Genomic DNA was isolated from spleens of WT (n = 5) and Cd27–/– 
(n = 3) CML mice and analyzed by real-time PCR. ΔΔCt values of human c-abl were normalized to ΔΔCt values of murine c-abl. (C) Expression of 
human c-abl mRNA in FACS-purified, pooled LSCs from WT (n = 19) and Cd27–/– (n = 21) CML mice 20 days after transplantation. (D) Expression 
of BCR/ABL-GFP in lin– BM cells of WT (n = 37) and Cd27–/– (n = 45) CML mice (pooled data from 7 independent experiments). (E) Blood smears 
(upper row) and cytospins (lower row) of naive BL/6, WT CML, and Cd27–/– CML mice. Scale bars: 20 μm. (F) Numbers of BCR/ABL-GFP+ granu-
locytes/μl blood (n = 8 mice per group) and (G) Kaplan-Meier survival curves resulting from primary transplantations of BCR/ABL-GFP–transduced 
BL/6 (black line, n = 13) versus Cd27–/– (dotted line, n = 15) BM cells into BL/6 recipients (pooled data from 2 independent experiments). (H) LSC 
numbers per mouse 15 days (n = 5 mice per group) and 20 days (n = 15 mice per group) after transplantation. (I) Numbers of lin–, BCR/ABL-GFP+ 
cells per mouse 20 days after transplantation (n = 15 mice per group). Data are displayed as mean ± SEM. Statistics: Student’s t test (B–D, I), 
2-way ANOVA (F), log-rank test (G), and 1-way ANOVA (H). Cells/mouse = cells from both femora, tibiae, and humeri.
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3-fold higher than in Cd27–/– LSCs (Figure 3B). There were no sig-
nificant differences in BrdU incorporation among Cd27–/– LSCs 
and empty GFP vector–transduced Cd27–/– HSCs or naive BL/6 or 
Cd27–/– HSCs (Figure 3B and data not shown). In addition, we per-
formed an analysis of the cell cycle status using DAPI staining. The 
fraction of WT LSCs in S phase was approximately 2-fold higher 
than that of Cd27–/– LSCs (Figure 3C). Again, no significant differ-
ences were observed in the cell cycle status of naive control HSCs 
(Figure 3D). Analysis of LSC viability using 7-aminoactinomycin 
D (7-AAD) and annexin V did not reveal significant differences 
between WT and Cd27–/– CML animals (Supplemental Figure 9).
As depicted in Figure 1B, LSCs in WT CML consist of a popula-
tion of CD27hi LSCs and, due to ligation with CD70 (Figure 1, D 
and E), a population of CD27lo LSCs. Isolation of these 2 popula-
tions allowed us to study the effect of CD27 ligation on LSCs in 
vivo. Functional analysis of FACS-sorted CD27hi and CD27lo LSCs 
from WT CML animals revealed that BrdU incorporation in CD27lo 
LSCs was greatly increased (Figure 3E). In addition, FACS-sorted 
CD27lo LSCs formed significantly more colonies and cells in meth-
ylcellulose than CD27hi LSCs (Figure 3F).
Taken together, these observations indicate that CD27 signaling 
on LSCs increases LSC proliferation.
CD27 signaling promotes leukemia progression in secondary CML. 
Transduction of BM with BCR/ABL-GFP retroviral particles 
may lead to integration in HSCs but also in progenitor cells. To 
compare CML development after transplantation of identical 
numbers of LSCs, 2 × 104 LSCs from WT or Cd27–/– CML were 
isolated by FACS 20 days after primary transplantation and 
Figure 3
CD27 signaling enhances proliferation and cell cycle progression of LSCs in vivo. (A and B) Analysis of (A) naive HSC and (B) LSC proliferation 
by BrdU incorporation. Empty GFP-transduced naive Cd27–/– HSCs were used as a control in B. (C and D) Cell cycle analysis by DAPI stainings 
of (C) LSCs and (D) naive HSCs. Cells of n = 3–8 animals per group were pooled in each experiment. Pooled data from 4 independent experi-
ments are shown. (E) LSCs pooled from 6 WT CML mice were separated by FACS sorting based on surface expression of CD27 (lo or hi), and 
BrdU incorporation was analyzed by FACS. (F) 103 FACS-purified, CD27 lo- or hi-expressing WT LSCs were plated into methylcellulose, and 
colonies and cells per well were enumerated 7 days later. (G–J) 2 × 104 LSCs from WT or Cd27–/– CML animals were isolated by FACS 20 days 
after primary transplantation and secondarily transplanted into irradiated (4.5 Gy) BL/6 recipients. (G) Granulocyte counts/μl blood (n = 3 mice 
per group) and (H) Kaplan-Meier survival curves resulting from secondary transplantations of WT (black line, n = 5) or Cd27–/– (dotted line, n = 7) 
LSCs (pooled data from 2 independent experiments). (I) Lin– c-kithi BCR/ABL-GFP+ myelogenous progenitor cell numbers and LSC numbers per 
mouse in the BM of BL/6 recipients 4 days after secondary transplantation. (J) Cell cycle analysis by DAPI stainings of LSCs in secondary CML 
20 days after transplantation. BrdU incorporation was calculated as the difference in the percentage of α–BrdU-PE+ minus isotype control–PE+ 
cells. Data are displayed as mean ± SEM. Statistics: Student’s t test (A–F, I, and J), 2-way ANOVA (G), and log-rank test (H). Cells/mouse = 
cells from both femora, tibiae, and humeri.
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injected into irradiated (4.5 Gy) secondary BL/6 recipients. WT 
LSCs regularly induced CML in secondary recipients, whereas 
CD27-deficient LSCs failed to effectively establish CML (Fig-
ure 3, G and H). A genomic real-time PCR of secondary recipi-
ents indicated a similar integration of the BCR/ABL oncogene 
(Supplemental Figure 10). To exclude a potential role of CD27 
on LSC homing, we assessed the numbers of myelogenous leu-
kemia progenitors and LSCs in the BM after secondary trans-
plantation into irradiated BL/6 mice. There was no significant 
difference in the numbers of lin–, c-kithi, BCR/ABL-GFP+ pro-
genitor cells or LSCs in secondary hosts 4 days after transplan-
tation of 2 × 104 purified WT or Cd27–/– LSCs (Figure 3I).
In analogy to primary CML, we analyzed LSC proliferation in 
secondary CML by DAPI staining 20 days after secondary LSC 
transplantation. Secondary WT LSCs proliferated significantly 
more than secondary Cd27–/– LSCs (Figure 3J), further confirming 
that CD27 signaling induces LSC proliferation.
CD27 signaling enhances Wnt signaling in LSCs. To dissect the mecha-
nism of CD27 signaling on LSCs, we first analyzed a hematopoiesis-
specific gene expression profile of WT and Cd27–/– LSCs. FACS 
sorting of LSCs resulted in approximately 1 × 104 LSCs per CML 
mouse. Therefore, to reach sufficient cell numbers for gene expres-
sion profiling, FACS-sorted LSCs from 8 CML mice per group 
were pooled for this experiment. Using an RT2 Profiler PCR Array, 
we assessed 84 genes related to hematopoiesis. CD27 signaling 
induced the expression of 12 genes and repressed 19 genes in LSCs 
(Figure 4A and Supplemental Table 1). Interestingly, target genes of 
the canonical Wnt pathway, i.e., Runx1, Wnt3a, Inha, Lef1, Vegfa, and 
Dll1, were strongly upregulated. In addition, genes involved in cell 
cycle transition (Pax5, Hdac5) and HSC differentiation (Gata1) were 
upregulated by CD27 signaling. In contrast, genes involved in HSC 
quiescence (Tek/Tie2) and in normal blood cell development and 
differentiation (Cd3g, Cd4, Cd8a, Cd14, Blnk) were downregulated.
To further confirm and extend the results from the PCR array, 
we investigated the expression of additional Wnt target genes in 
FACS-sorted WT versus Cd27–/– LSCs by real-time RT-PCR. Using 
Runx1 as a positive control, we found that the expression of Wnt 
target genes Wisp1, Notch1, Ccnd1, Myc, and Hoxb4 was at least 
3-fold higher in WT than in Cd27–/– LSCs (Figure 4B). In addition, 
we performed a lentivirus-based T cell transcription factor/lym-
phoid enhancer factor (Tcf/Lef) reporter luciferase assay to mea-
sure activation of the Wnt pathway in FACS-purified WT and 
Cd27–/– LSCs (Figure 4C). The Wnt pathway was more activated in 
WT than in Cd27–/– LSCs. To provide extra CD27 ligation in vitro, 
purified B cells isolated from Cd70 Tg (Cd70-Tg) mice that con-
stitutively express CD70 under the control of the CD19 promoter 
were added to the purified LSCs. Additional CD27 stimulation 
profoundly increased activation of the Wnt pathway in WT LSCs, 
whereas no effect could be observed in Cd27–/– LSCs (Figure 4C).
In summary, these findings indicate that triggering CD27 on 
LSCs activates the Wnt pathway.
CD27 signaling increases nuclear localization of active β-catenin in 
LSCs. Activated β-catenin is the key mediator of the Wnt sig-
naling pathway (24). In CML, β-catenin is constantly active by 
Figure 4
CD27 signaling enhances Wnt signaling in LSCs. (A) Real-time RT-PCR array of hematopoietic genes in LSCs sorted and pooled from WT CML 
mice (n = 8) compared with Cd27–/– CML mice (n = 8). Only genes that displayed a 4-fold or greater change are shown. (B) Quantitative real-time 
RT-PCR of selected Wnt target genes in pooled LSCs from WT (n = 19) versus Cd27–/– (n = 21) CML mice. (C) Tcf/Lef luciferase reporter assay 
of pooled LSCs from WT and Cd27–/– CML mice (n = 5 animals per group). Data are displayed as mean ± SEM. Statistics: 1-way ANOVA.
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BCR/ABL-mediated tyrosine phosphorylation (25). We ana-
lyzed the expression and localization of active β-catenin by 
immunofluorescence stainings of FACS-sorted LSCs (Figure 5, 
A–C). Sum fluorescence intensity (SFI) of active β-catenin was 
similar in naive BL/6 and Cd27–/– HSCs. In contrast, the SFI of 
active β-catenin was significantly higher in LSCs than in HSCs. 
However, no difference in SFI was observed between WT and 
Cd27–/– LSCs, indicating a similar expression of active β-catenin 
independently of CD27 signaling (Figure 5B). Interestingly, 
active β-catenin was preferentially localized in the nucleus in 
LSCs with intact CD27 signaling, whereas only a minority of 
normal HSCs or Cd27–/– LSCs expressed β-catenin in the nucle-
us (Figure 5C). These data provide evidence that CD27 signal-
ing on LSCs increases nuclear translocation of active β-catenin, 
a key step in the transcription of Wnt target genes.
CD27 signaling increases nuclear localization of TNIK in LSCs. TNIK 
interacts with TRAF2, an important scaffold protein involved 
in CD27 signaling (26) and is a fundamental activator of Tcf4/ 
β-catenin–mediated Wnt target gene transcription (27, 28). 
However, whether TNIK is expressed and functional in HSCs or 
LSCs has not been analyzed so far. We found TNIK expression 
on the protein level by immunofluorescence (Figure 5D) and on 
the mRNA level by quantitative real-time RT-PCR (Supplemen-
tal Figure 11). TNIK SFI was significantly higher in WT than in 
Figure 5
CD27 signaling increases nuclear localization of active β-catenin and TNIK in LSCs. (A) Immunostainings for active β-catenin in LSCs from WT 
and Cd27–/– CML mice. GFP, DAPI, β-catenin, and the merging of DAPI and β-catenin are shown. Scale bars: 5 μm. (B) SFI of active β-catenin 
in naive HSCs and CML LSCs. (C) Percentage of naive HSCs and CML LSCs positive for nuclear active β-catenin. (A–C) 90–460 cells were 
analyzed. (D) Immunostainings for TNIK in LSCs from WT and Cd27–/– CML mice. GFP, DAPI, TNIK, and the merging of DAPI and TNIK are 
shown. Scale bars: 10 μm. (E) SFI of TNIK in naive HSCs and CML LSCs. (F) Percentage of naive HSCs and CML LSCs positive for nuclear 
TNIK. (D–F) 47–528 cells were analyzed. (A and D) For clarity, cells in some images were spliced together from the same microscopic field of 
view. Data are displayed as mean ± SEM. Statistics: 1-way ANOVA.
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Cd27–/– LSCs. Additionally, TNIK was expressed at significantly 
higher levels in LSCs than in HSCs (Figure 5E). Nuclear TNIK 
expression was significantly higher in WT LSCs than in Cd27–/– 
LSCs, comparable to the preferential localization of active 
β-catenin in the nucleus in CD27-competent LSCs (Figure 5F). 
No difference in nuclear TNIK expression was observed in naive 
control HSCs. Therefore, CD27 signaling on LSCs increases 
nuclear translocation of the transcriptional activator TNIK.
CD27 signaling increases colony formation of LSCs in a Wnt/β-catenin–
dependent manner. LSCs were functionally analyzed in vitro for their 
capacity to form colonies in methylcellulose. FACS-purified LSCs 
from WT and Cd27–/– CML mice isolated 20 days after transplanta-
tion formed equal numbers of colonies in methylcellulose (Figure 
6A). To address the effect of CD70-mediated CD27 stimulation on 
LSCs directly, we sorted GFP– control HSCs and BCR/ABL-GFP+ 
LSCs from individual WT CML mice and incubated these cells in 
the presence of irradiated (10 Gy) CD19+ B cells from either naive 
BL/6 mice or from Cd70tg mice. CD27 signaling on GFP– control 
HSCs decreased colony formation. In contrast, LSCs formed signifi-
cantly more colonies after triggering CD27 (Figure 6B). The increase 
in the number of colonies was reflected by a parallel increase in the 
cell numbers isolated from the methylcellulose cultures after CD27 
triggering (Figure 6B). These results indicate that, in contrast to nor-
mal HSCs, CD27 signaling on LSCs increases colony formation.
To determine whether active β-catenin is responsible for the 
observed increase in colony and cell numbers after CD27 trigger-
ing, we cultured CD27-stimulated LSCs in the presence or absence 
of the cyclooxygenase inhibitor indomethacin (29). Indomethacin 
enhances the degradation of active β-catenin by blocking PGE2 syn-
thesis (30). Indomethacin did not affect colony formation and cell 
numbers without CD27 stimulation. However, indomethacin treat-
ment significantly decreased colony formation and cell numbers 
after LSC coculture with Cd70tg CD19+ B cells (Figure 6, C and D).
In the next experiment, we analyzed the role of extracellular Wnt 
ligands on the CD27-mediated increase in LSC numbers. Addition-
al stimulation of the Wnt pathway in WT LSCs by providing exog-
enous Wnt-3a did not further increase colony formation, regardless 
of CD27 stimulation (Figure 6E). In contrast, blocking extracellular 
Wnt ligands by addition of secreted frizzled-related protein 2 (Sfrp-
2), a soluble Wnt antagonist, completely inhibited the CD27-medi-
ated increase in LSC colony formation (Figure 6E).
These results indicate that CD27-mediated LSC proliferation 
is mediated by the Wnt/β-catenin pathway and is dependent on 
extracellular Wnt ligands.
Blocking CD70-CD27 interaction prolongs survival of WT CML mice. After 
having provided evidence that CD27 signaling on LSCs increases 
progression of CML, we next sought to analyze whether blocking 
the CD70-CD27 interaction by mAb treatment can be used to treat 
Figure 6
CD27 signaling increases the colony formation of LSCs in a Wnt/β-catenin–dependent manner. (A) 103 FACS-purified LSCs from WT or Cd27–/– 
CML mice were directly plated in methylcellulose, and colonies were enumerated 7 days later. Pooled data from 2 independent experiments each 
run in triplicate are shown. Values of colonies are shown in relation to the mean of WT LSCs (=100%). (B) 5 × 103 FACS-purified GFP– HSCs 
(n = 7) or BCR/ABL-GFP+ LSCs (n = 8) from individual WT CML mice were incubated overnight with 5 × 104 irradiated (10 Gy) naive BL/6 or 
Cd70tg CD19+ B cells, followed by plating in methylcellulose. Colonies and total cells were enumerated after 7 days. Data illustrate the percent-
age change in colony or cell formation of naive BL/6 CD19+ versus CD70-Tg CD19+ coincubations in each individual WT CML sample (naive 
BL/6 CD19+ = 100%). Pooled results of 3 independently performed experiments are shown. (C–E) 5 × 103 FACS-purified LSCs from pooled WT 
CML mice were incubated overnight with or without 5 × 104 irradiated (10 Gy) naive BL/6 or Cd70tg CD19+ B cells in the presence or absence of 
(C and D) 60 μM indomethacin or (E) 100 ng/ml Wnt-3a or 1 μg/ml Sfrp-2, followed by plating in methylcellulose (± the respective compound). 
Numbers of colonies (C and E) and cells (D) per well were assessed 7 days later. Each condition was run in quadruplicate to sextuplicate. Data 
are displayed as mean ± SEM. Statistics: Student’s t test.
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Figure 7
Blocking the CD70-CD27 interaction inhibits LSC proliferation and prolongs survival. WT CML mice were treated i.p. every other day with 300 
μg FR70 or control IgG from rat serum starting at the day of transplantation. (A) Numbers of BCR/ABL-GFP+ granulocytes/μl in blood (n = 5 
animals per group). (B) Kaplan-Meier survival curves. Pooled data from 2 independent experiments with FR70-treated (dotted line, n = 10) or 
IgG-treated (black line, n = 9) animals are shown. (C) Numbers of lin– BCR/ABL-GFP+ myelogenous progenitor cells and (D) LSCs per mouse 
20 days after transplantation (n = 18 mice per group, pooled data from 2 independent experiments). (E and G) Immunostainings for (E) active 
β-catenin (spliced together from the same microscopic field of view) and (G) TNIK in LSCs from WT CML mice treated with IgG or FR70, 20 days 
after transplantation. Overlays of DAPI and β-catenin and DAPI and TNIK, respectively, are shown. Scale bars: 10 μm. (F and H) Percentages 
of LSCs positive for (F) nuclear active β-catenin and (H) nuclear TNIK. 175–216 cells were analyzed per group. (I) Cell cycle analysis by DAPI 
staining of LSCs from IgG-treated and FR70-treated WT CML mice. (J) 20 days after primary transplantation, 3 × 106 BM cells from IgG-treated or 
FR70-treated WT CML mice were pooled and secondarily transplanted into irradiated (4.5 Gy) BL/6 mice. Kaplan-Meier survival curves resulting 
from secondary transplantations are shown. Data are displayed as mean ± SEM. Statistics: 2-way ANOVA (A), log-rank test (B and J), Student’s 
t test (C, D, F, H, and I). Cells/mouse = cells from both femora, tibiae, and humeri.
Downloaded from http://www.jci.org on July 10, 2015.   http://dx.doi.org/10.1172/JCI45977
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 122   Number 2   February 2012 633
CML. The treatment of WT CML mice with CD70-blocking Ab FR70 
delayed CML progression and prolonged survival when compared 
with WT CML mice treated with control IgG (Figure 7, A and B). 
FR70 treatment reduced numbers of myelogenous leukemia pro-
genitor cells and LSCs (Figure 7, C and D, and Supplemental Figure 
12), as analyzed by FACS 20 days after transplantation. Furthermore, 
in analogy to what we observed in WT and Cd27–/– LSCs, significantly 
lower amounts of active β-catenin and TNIK were detected in nuclei 
of FACS-sorted LSCs from FR70-treated mice (Figures 7, E–H). This 
resulted in reduced proliferation of LSCs in FR70-treated CML ani-
mals (Figure 7I). To define the effect of FR70 treatment on LSCs in 
vivo in more detail, we performed a secondary transplantation of 
IgG- or FR70-treated CML. Twenty days after primary transplanta-
tion, we secondarily transplanted 3 × 106 whole BM cells from IgG- 
or FR70-treated WT CML mice into irradiated (4.5 Gy) BL/6 mice. 
Mice that received FR70-treated CML BM survived significantly lon-
ger than mice that received IgG-treated CML BM (Figure 7J).
Of note, treatment with FR70 Ab blocked CD70-CD27 interac-
tions not only on the LSC level, but also on lymphocytes, possi-
bly resulting in impaired activation of T cells (15, 22). Therefore, 
despite these negative effects on T cell activation, blocking CD70-
CD27 interaction prolonged overall survival of WT CML mice.
CD27 is expressed on human CML progenitor cells. To validate the sig-
nificance of our findings for human disease, we first analyzed the 
expression of CD27 on MACS-enriched CD34+ BM cells in aspira-
tions from patients that underwent BM biopsy for other reasons 
than leukemia (healthy donors). CD34+ BM cells expressed CD27 as 
analyzed by FACS (Figure 8A). In a next step, BM biopsies from 10 
untreated, newly diagnosed CML patients (mean age: 50 years, range: 
26–72 years; mean leukocyte count: 70 × 109/l, range: 17–160 × 109/l) 
were examined by 2 surgical pathologists for CD27 expression and 
coexpression with CD34 by immunohistochemistry. In all cases, 
CD27-positive cells could be found that fulfilled the morphological 
criteria of mature lymphocytes and plasma cells. Besides, CD27-posi-
tive cells (0.025% ± 0.004% of all nucleated cells) were found display-
ing the morphological characteristics of myeloid progenitor/stem 
cells with enlarged, centrally located nuclei and immature chromatin 
(Figure 8B). In double stainings, such cells stained positive for both 
CD34 and CD27 (Figure 8C). In every single case, adequate inter-
nal controls stained as expected: vessels, CD34+ and CD27–; mature 
myeloid cells, CD27–; and plasma cells, CD27+ (data not shown).
To functionally analyze CD27 signaling in human leukemia cells, 
we used the BCR/ABL+ leukemia cell line SD-1, which expresses 
both CD27 and CD70 (data not shown). Blocking CD27 signaling 
by monoclonal anti-CD27 Ab resulted in reduced cell proliferation 
(Figure 8D) compared with untreated or control IgG–treated cells. 
However, blocking CD27 did not affect apoptosis, as analyzed by 
annexin V stainings (data not shown). In addition, we analyzed 
the activation of the Wnt pathway in SD-1 cells treated with anti-
CD27 Ab or control IgG. Blocking CD27 strongly reduced Tcf/Lef 
reporter activity (Figure 8E).
The CD27-TRAF2-TNIK signaling axis induces the Wnt pathway in 
human leukemia cells. To investigate the intracellular CD27 sig-
naling pathway in human leukemia cells in more detail, we first 
Figure 8
Expression and function of CD27 on human leukemia cells. (A) Human BM aspirates from healthy donors who underwent biopsy for reasons 
other than leukemia were enriched for CD34+ cells by MACS, and expression of CD34 and CD27 were analyzed by FACS. 1 representative 
experiment out of 3 is shown. Gray line, isotype control; black line, CD27 staining. (B and C) Representative immunohistochemistries for (B) 
CD27 (brown) and (C) CD34 (brown) and CD27 (red) on BM biopsy samples of untreated CML patients (n = 10). Scale bars: 5 μm. Black arrows 
indicate CD27+ progenitor/stem cells. 7,500–17,000 cells/biopsy were analyzed. (D) 105 BCR/ABL+ SD-1 cells were cultured in the presence 
or absence of 10 μg/ml mouse control IgG or blocking anti-CD27 Ab for 3 days. For the last 4 hours of culture, 10 μM of BrdU was added to the 
medium; cells were then harvested and BrdU incorporation was analyzed by FACS. Each condition was run in duplicate. (E) Tcf/Lef luciferase 
reporter assay of SD-1 cells cultured in the presence of mouse IgG control Ab or CD27 blocking mAb for 24 hours. Each condition was run in 
duplicate. Data are displayed as mean ± SEM. Statistics: 1-way ANOVA (D); Student’s t test (E).
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performed coimmunoprecipitation studies for the interaction of 
TRAF2 and TNIK. This interaction has been described before by 
Fu et al. in T293 cells (26). Western blot analysis revealed that both 
TNIK and TRAF2 are expressed in SD-1 cells and T293 control 
cells (Figure 9A). More importantly, TNIK coimmunoprecipitated 
with TRAF2, indicating that these molecules functionally interact 
in SD-1 cells (Figure 9A).
To analyze the role of TRAF2 and TNIK on the expression of Wnt 
target genes and the subcellular localization of active β-catenin, we 
stably silenced TNIK or TRAF2 in SD-1 cells by shRNAs and com-
pared these with scrambled RNA–expressing control cells. Wnt tar-
get genes were approximately 3-fold downregulated after knock-
down of TNIK or TRAF2 in SD-1 cells (Figure 9B). Furthermore, 
knockdown of TNIK or TRAF2 resulted in significantly lower 
amounts of nuclear active β-catenin in SD-1 cells (Figure 9, C–E).
In addition, we investigated the effect of TNIK or TRAF2 knock-
downs on the growth of SD-1 cells in comparison with treatment 
with blocking anti-CD27 mAb. TNIK (Figure 9F) or TRAF2 (Fig-
ure 9G) knockdowns had an inhibitory effect on SD-1 cell growth 
similar to that of blocking CD27 signaling. Importantly, combin-
ing knockdowns of TNIK or TRAF2 with anti-CD27 Ab treatment 
did not additionally inhibit cell growth, indicating that the effect 
of CD27 signaling on SD-1 cell proliferation is exclusively medi-
ated via TRAF2/TNIK.
In summary, these findings indicate that CD27 is expressed on 
CD34+ cells in the BM of healthy donors and CML patients and 
that CD27 signaling on leukemia cells increases Wnt pathway 
activity via TRAF2/TNIK.
Discussion
In addition to the tumor-protective role of the host immune 
system, it has become increasingly evident that parts of the host 
immune responses favor tumor progression (31). In the present 
study, we provide evidence that CD27 signaling on LSCs and early 
myelogenous leukemia progenitors promotes leukemia progres-
sion. Previous studies have already demonstrated that CD27 is dif-
ferentially expressed on murine HSCs, subdividing the HSC popu-
lation into cells with short-term (CD27+) and long-term (CD27–) 
hematopoietic activity (16). In contrast, the expression and func-
tion of CD27 on LSCs has not been analyzed so far.
Like HSCs, LSCs and myelogenous leukemia progenitor cells, 
but not differentiated granulocytes, express CD27. However, LSCs 
and leukemia progenitor cells consist of a CD27hi and a CD27lo/neg 
population. Blocking the CD70-CD27 interaction with FR70 Ab 
in vivo resulted in upregulation of CD27 on CD27lo/neg LSCs, indi-
cating recent CD70-CD27 ligation in vivo and consequent shed-
ding of CD27 (12). CD70 is expressed on activated lymphocytes 
and subsets of mature DCs and, indeed, activated CD8+ and CD4+ 
T cells and NK cells have been documented in CML patients (32, 
33). In addition, we documented CD70 expression in BM-infiltrat-
ing immune cells in CML, preferentially by CD3+ T cells.
LSCs possess biological features that are different from those of 
HSCs and are crucially important for their malignant characteris-
tics (34–36). CD27 signaling on HSCs and early progenitor cells 
decreased leukocyte differentiation (17). In contrast, we found 
increased numbers of LSCs and all subsequent differentiation steps 
including myelogenous leukemia CMPs, GMPs, and differentiated 
Figure 9
CD27-TRAF2-TNIK signaling induces the Wnt pathway in human leukemia cells. (A) Expression of TNIK and TRAF2 in BCR/ABL+ SD-1 cells and 
control T293 cells (left panel) and immunoprecipitation for TRAF2 in SD-1 cells, followed by Western blot for TRAF2 and TNIK (right panel). (B) 
Quantitative real-time RT-PCR of selected Wnt target genes in SD-1 cells stably expressing a scrambled shRNA (scrRNA), an shRNA against 
TNIK (shTNIK), or TRAF2 (shTRAF2). (C) Immunostainings for active β-catenin in SD-1 cells stably expressing scrRNA, shTNIK, or shTRAF2. 
Overlays of DAPI and β-catenin are shown. Scale bars: 5 μm. (D and E) Percentages of nuclear active β-catenin in SD-1 cells stably expressing 
(D) scrRNA versus shTNIK and (E) scrRNA versus shTRAF2. 110–226 cells were analyzed per group in 2 independent experiments. (F and 
G) 105 parental SD-1 cells, SD-1 cells stably expressing scrRNA, (F) shTNIK, or (G) shTRAF2 were cultured in the presence or absence of 10 
μg/ml mouse control IgG or blocking anti-CD27 Ab. Numbers of viable cells were daily determined by trypan blue staining. Each condition was 
run in duplicate in 2 independent experiments. Data are displayed as mean ± SEM. Statistics: Student’s t test (D and E); 2-way ANOVA (F and 
G) (P value indicates comparison of each of the upper 4 versus each of the lower 5 conditions).
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granulocytes in CML mice with intact CD27 signaling on LSCs. 
This difference may be explained by the fact that the tyrosine kinase 
BCR/ABL by itself mediates effects on signal transduction path-
ways affecting cell survival, proliferation, and differentiation. BCR/
ABL+ LSCs and committed leukemia progenitors are capable of self 
renewal (37–41). We have now found that CD27 signaling increases 
the number of LSCs by inducing cell division and proliferation.
Various pathways have been identified that are involved and coop-
erate in HSC self renewal and proliferation, such as the Notch and 
Wnt pathways (24, 42–44). Alterations in Wnt signaling have been 
reported in hematopoietic malignancies such as acute lympho-
blastic leukemia, myelodysplastic syndromes, and CML (44–48). 
Surprisingly, we found that CD27 signaling activated the Wnt 
pathway and upregulated Wnt target genes. It is well documented 
that triggering CD27 leads to recruitment of TRAF2 to its cytosolic 
domain. TRAF2 serves as an adaptor protein for kinases to orches-
trate common signaling pathways, such as the NF-κB pathway and 
the JNK/AP1 and PI3K/Akt pathways (49), but a link to the Wnt 
pathway has not yet been documented. Recently, TNIK was shown 
to be an essential activator of the Wnt pathway in colorectal cancer 
(26–28). Our results indicate that TNIK is expressed in HSCs and 
LSCs and, therefore, may link CD27 signaling to the Wnt path-
way. Importantly, active β-catenin and TNIK were preferentially 
localized in the nucleus of WT LSCs, but not of Cd27–/– or FR70-
treated LSCs. The β-catenin/TNIK complex is essential for the 
TNIK-mediated phosphorylation of Tcf4 and subsequent Tcf4/
Lef-driven transcriptional activation of Wnt target genes (27).
To functionally analyze whether CD27 signaling induces prolif-
eration of LSCs via the Wnt pathway, we inhibited β-catenin in vitro 
by indomethacin (30). In the presence of indomethacin, the effect 
of CD27 signaling on LSC proliferation was completely blocked. 
Additional stimulation of the Wnt pathway by providing exogenous 
Wnt-3a did not further increase colony formation, indicating satura-
tion in the extracellular activation of Wnt signaling through frizzled 
(FZD) receptors on LSCs. In contrast, addition of the extracellular 
Wnt antagonist Sfrp-2 blocked the effect of CD27 stimulation. This 
suggests that CD27-mediated signaling to β-catenin is dependent 
on extracellular, probably autocrine-secreted, Wnt ligands and indi-
cates that TNIK/β-catenin is the main pathway of CD27 signaling–
induced proliferation of LSCs. In CML, active β-catenin is stabilized 
by BCR/ABL-mediated tyrosine phosphorylation (25). We propose 
that BCR/ABL and CD27 cooperate at the level of β-catenin/TNIK-
induced transcriptional activation of Wnt target genes to drive LSC 
proliferation and CML progression (Figure 10).
Figure 10
Model of CD27-induced Wnt pathway acti-
vation in LSCs. Binding of Wnt proteins to 
FZD leads to activation of β-catenin in the 
cytoplasm. Subsequently, TNIK binds to 
active β-catenin and this complex is recruit-
ed to the nucleus, where TNIK directly 
phosphorylates Tcf, converting the Tcf/Lef-
complex from a transcriptional repressor 
into a transcriptional activator of Wnt target 
genes. In CML, the Wnt signaling pathway 
is constantly activated by BCR/ABL-medi-
ated tyrosine phosphorylation of active 
β-catenin, resulting in enhanced stability and 
leading to pathological LSC proliferation/dif-
ferentiation. CD27 signaling leads to recruit-
ment of TRAF2 and subsequent activation 
of TNIK, promoting nuclear translocation of 
the active β-catenin/TNIK complex. There-
by, CD27 signaling contributes to increased 
transcription of Wnt target genes.
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CML stem cells seem resistant to most therapeutic interventions, 
such as chemotherapy, irradiation, and administration of tyrosine 
kinase inhibitors. Even during therapy, quiescent, self-renewing 
LSCs remain in the BM and are responsible for the refractoriness 
and relapse of CML (50). Therefore, a possible curative treatment 
must target LSCs. Our results indicate that CD27 signaling enhanc-
es LSC proliferation and expansion and promotes disease progres-
sion via the Wnt pathway, an essential pathway for self renewal of 
HSCs and CML LSCs (51). In our model, only LSCs and leukemia 
progenitors were CD27 deficient, whereas the immune system of 
the mouse was CD27 competent. However, treatment of WT CML 
mice with a monoclonal CD70-blocking Ab indicated that disease 
progression is delayed and survival is prolonged despite the fact that 
CD27 signaling was blocked on both LSCs and lymphocytes.
In 1995, Lansdorp et al. reported that CD27 is not expressed on 
CD34+ BM cells (52). In contrast, we demonstrate CD27 expres-
sion by FACS on CD34+ BM cells of healthy donors. In addition, 
we show by immunohistochemistry that morphologically identi-
fied and CD34+ progenitor/stem cells from CML patients express 
CD27. In parallel to our findings in the murine CML model, the 
CD27-TRAF2-TNIK signaling axis activated the Wnt pathway and 
induced proliferation of a human BCR/ABL+ leukemia cell line.
In summary, our data indicate that blocking the CD70-CD27 
interaction or targeting intracellular mediators of the CD27 sig-
naling pathway may provide an additional therapeutic option 
for treating CML on the level of LSCs. In this study, we identi-
fied CD27 signal transduction as a new link between the immune 
system and Wnt signaling/leukemia development in CML. Wnt 
signaling is essential for LSC and leukemia GMP development and 
self renewal in CML and other types of leukemia, such as acute 
myelogenous leukemia and acute lymphoblastic leukemia (29, 39, 
51, 53). Further studies will reveal whether targeting CD27 signal-
ing to inhibit the Wnt/β-catenin pathway is a therapeutic oppor-
tunity in acute leukemia as well.
Methods
Mice. BL/6 mice were from RCC Ltd., Cd27–/– mice (BL/6 background) were 
from J. Borst (National Cancer Institute, Amsterdam, The Netherlands) 
(22), and Cd70tg mice (BL/6 background) were from R. van Lier (University 
of Amsterdam, Amsterdam, The Netherlands) (54). Animal experiments 
were approved by the Veterinary Office of the Canton Bern and performed 
according to Swiss laws for animal protection.
Patients. Aspirations from patients that underwent BM biopsy for rea-
sons other than leukemia (healthy donors, n = 3 males; age, 19–43 years) 
were obtained at the University Hospital Bern in 2011. BM biopsy samples 
were obtained from randomly selected untreated CML patients (n = 10, 6 
females, 4 males; age, 26–72 years) diagnosed at the Institute of Pathology 
at the University Hospital Basel between 2008 and 2010. All CML patients 
possessed a BCR/ABL translocation as tested by molecular analysis from 
the blood. Analysis of BM samples was approved by the local ethical com-
mittees, and all patients gave written informed consent.
Abs. α-CD27 PE and allophycocyanin (APC), α–CD16/32-PE-Cy7, α–c-kit- 
PE-Cy7 and α–c-kit-APC–Alexa Fluor 750, α–Sca-1-PerCP-Cy5.5 (where 
PerCP indicates perinidin-chlorophyll protein), and α–Sca-1-APC, α–Ly6G-
PE, α–Gr1-APC, α–IL-7Rα-biotin, α–CD3ε-biotin, α–CD19-biotin, α–Gr1-
biotin and α–Ter119-biotin were from eBioscience. α–BrdU-PE (3D4) and 
isotype and 7-amino-actinomycin-D (7-AAD) were from BD Pharmingen. 
Annexin V–biotin was produced as described (55). α-CD70 (FR70) was 
from BioXCell, and IgG from rat serum was from Sigma-Aldrich. α-CD27 
(1A4) and mouse IgG1 (15H6) were from Beckman Coulter.
Retroviral particles. The retroviral vector pMSCV-p210BCR/ABL-IRES-GFP 
and the packaging vector pIK6 were a gift from J. Schwaller (University of 
Basel). Retroviral particles were produced and titrated as described (9, 10).
CML model. CML was induced and monitored as described (9, 10). Briefly, 
4 × 106 BM cells of 5-fluorouracil–pretreated mice were transduced twice in 
transplant medium with 1 × 105 retroviral particles through spin infection. 
1 × 105 transduced BM cells were injected i.v. into previously irradiated (4.5 
Gy) BL/6 recipient mice. 5 × 105 transduced BM cells were incubated for 3 
days in transplant medium, and GFP expression was analyzed by FACS.
Starting from 2 weeks after transplantation, mice were daily monitored 
for signs of morbidity (weight loss, failure to groom, abnormal gait, and 
posture) and were repeatedly bled for determination of blood granulocyte 
numbers. Mice were euthanized when granulocyte counts reached more 
than 105/μl, when more than 20% of weight before transplantation was 
lost, or when failure to groom or abnormal gait or posture was present. 
Mice were dissected, gross anatomy of lungs, liver, and spleen was analyzed, 
and spleen weights were measured.
Blood smears and cytospins. Methodology for blood smears and cytospins 
is described in ref. 9.
Lineage depletion and flow cytometry. BM lineage depletion was performed 
using biotinylated Abs against red cell precursors (α-Ter119), B cells 
(α-CD19), T cells (α-CD3ε), and myeloid cells (α-Gr1), MACS α-biotin 
beads, and LS columns (Miltenyi Biotec). For analysis of myeloid progeni-
tors, lymphoid progenitors were removed by adding α–IL-7Rα-biotin.
Determination of granulocyte counts/μl was performed using Trucount 
Tubes (BD Biosciences). All samples were analyzed on a BD LSRII, and 
sorting was performed on a BD FACSAria (BD Biosciences). Data were ana-
lyzed using FlowJo software (TreeStar).
BrdU incorporation and cell cycle analysis. Animals were administered BrdU 
(0.8 mg/ml; Sigma-Aldrich) in drinking water for 8 days. FACS-sorted 
HSCs and LSCs were pooled and incubated in 1% PFA/PBS, 0.05% Tween-
20 overnight at 4°C. Samples were incubated in 125 Kunitz units DNase-I 
(Sigma-Aldrich) per 250 μl DNase buffer (4.2 mM MgCl2, 0.15 M NaCl; pH 
5) for 1 hour at 37°C. Staining was performed with α–BrdU-PE or isotype 
control–PE for 30 minutes at room temperature. For cell cycle analysis, 
FACS-sorted HSCs and LSCs were pooled and incubated in 1% PFA/PBS 
overnight at 4°C. Samples were permeabilized with 0.2% Triton X-100 for 
30 minutes at 4°C and labeled with 5 μg/ml DAPI (Roche).
Colony forming assays. 5 × 103 FACS-sorted HSCs or LSCs from CML mice 
were incubated overnight in transplant medium with a 10-fold excess of 
MACS-purified, irradiated (10 Gy) BL/6 or CD70-Tg CD19+ B cells in 96-
well V-bottom plates, followed by transfer into methocult base medium 
(Stemcell Technologies) supplemented with 15% FCS, 20% BIT (50 mg/
ml BSA in IMDM, 1.44 U/ml recombinant-human (rh) insulin [Actrapid; 
Novo Nordisk] and 250 ng/ml human holo transferrin [Prospec]), 100 μM 
2-β-mercaptoethanol, 2 mM l-glutamine, penicillin/streptomycin, and 
50 ng/ml recombinant-mouse SCF (rmSCF), 10 ng/ml rm–IL-3, 10 ng/ml 
rh-IL-6 and 50 ng/ml rm-Flt3-ligand (all from Prospec). In some experi-
ments, 60 μM indomethacin (Sigma-Aldrich), 10 mM lithium chloride 
(Sigma-Aldrich), 1 μg/ml Sfrp-2 (R&D Systems), or 100 ng/ml Wnt-3a 
(R&D Systems) was added to cultures. Colonies and cells were enumerated 
after 7 days (≥30 cells/colony).
Real-time RT-PCR. LSCs were FACS sorted and pooled into RNAprotect 
Cell Reagent (QIAGEN), and RNA was extracted and purified using the 
RNeasy Mini Kit (QIAGEN). Reverse transcription was performed using 100 
ng of RNA, random oligonucleotides, and AMV-RT (Roche). For quantita-
tive real-time RT-PCR, we used TaqMan Gene Expression Assays for TNIK, 
Runx1, Wisp1, Notch1, Ccnd1, Myc, Hoxb4, human c-Abl, Gapdh, and β-actin 
(Applied Biosystems). Readouts of plates and analysis of data were per-
formed on an ABI 7500 system and SDS2.3 software (Applied Biosystems).
Downloaded from http://www.jci.org on July 10, 2015.   http://dx.doi.org/10.1172/JCI45977
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 122   Number 2   February 2012 637
Real-time RT-PCR array. Reverse transcription was performed on 100 ng 
of RNA using the RT² Nano PreAMP cDNA Synthesis Kit (SABiosciences). 
cDNA was amplified using the RT² Nano PreAMP cDNA Primer Mix specif-
ic for the Hematopoietic Stem Cells and Hematopoiesis PCR Array (SABio-
sciences). Quantitative real-time RT-PCR was performed with RT2 SYBR 
Green/ROX qPCR Master Mix (SABiosciences) on the Hematopoietic Stem 
Cells and Hematopoiesis RT2 Profiler PCR Array (SABiosciences) using an 
ABI 7300 system (Applied Biosystems). Differences in gene expression were 
calculated using the software supplied on the SABiosciences website.
Genomic real-time PCR. 10 mg of spleens from primary and secondary BL/6 
CML and Cd27–/– mice were collected, and genomic DNA was extracted and 
purified using the DNeasy blood and tissue kit (QIAGEN). For quantitative 
real-time PCR, we designed DNA primers and probes for human ABL (forward: 
5′-AGGACAGCTCTTGATTTG-3′; reverse: 5′-GACAGATGGAAAGGACATG-
3′; probe: 5′-AAACAGGGTGCTAAAGCCAAC-3′) and murine c-abl (forward: 
5′-CTGCACTTGAAACTTCTC-3′; reverse: 5′-TACCGTCATTGAGCTATTC-
3′; probe: 5′-CACAGCCAGTCTCAGTTCAGG-3′). Probes were labeled at 5′ 
with FAM and at 3′ with BHQ-1 (Microsynth). 50 ng of DNA was analyzed by 
PCR amplification. Readouts of plates and analysis of data were performed on 
an ABI 7900 system and SDS2.3 software (Applied Biosystems).
Lentivirus-based reporter assay. In vitro Tcf/Lef reporter assay was performed 
as described (56). Briefly, 5 × 103 FACS-sorted LSCs from pooled WT or 
Cd27–/– CML animals were plated into individual wells of a 96-well U-bot-
tom plate in IMDM without antibiotics, supplemented with 10% FCS, 50 
ng/ml rm-SCF, 10 ng/ml rh–IL-11, 10 ng/ml rm-TPO, and 50 ng/ml rm-
Flt3-ligand (all from Prospec). Individual wells were transduced overnight 
at 37°C and 5% CO2 with Tcf/Lef lentiviral particles expressing firefly-
luciferase or the respective positive and negative control lentiviral particles 
(Cignal Lenti Tcf/Lef reporter [luc] kit; SABiosciences) at an MOI of 25, in 
the presence of 8 μg/ml SureEntry transduction reagent (SABiosciences) 
according to the manufacturer’s instructions. After 18 hours, medium was 
removed and LSCs were incubated in the presence or absence of a 10-fold 
excess of MACS-purified, irradiated (10 Gy) BL/6 or CD70-Tg CD19+ B cells. 
SD-1 cells were transduced as described above with an MOI of 10, and stable 
cell lines were generated under puromycin selection (2.5 μg/ml; Santa Cruz 
Biotechnology Inc.). Luciferase activity was measured 3 days later on an Infi-
nite 200 microplate reader (Tecan) by using the Steady-Glo Luciferase Assay 
System (Promega) according to the manufacturer’s instructions.
Immunofluorescence. LSCs and HSCs were FACS sorted on glass slides, 
fixed, and blocked with 5% goat serum/1% BSA in 0.1% PBS–Tween-20 for 
1 hour. After washing, slides were incubated for 2 hours with α–active–β-
catenin (8E7; Millipore), followed by incubation with α-mouse IgG–Alexa 
Fluor 594 (Invitrogen) for 90 minutes. Slides were counterstained with 
10 μg/ml DAPI. For TNIK immunostainings, slides were stained with 
αmouse-TNIK-Ab (Santa Cruz Biotechnology Inc.) and α–rabbit-IgG–
Alexa Fluor 594 (Invitrogen). Images were captured on an Eclipse E800 
microscope with a DXM-1200 camera and analyzed using NIS Elements 
BR 3.0 software (Nikon Instruments).
TNIK/TRAF2 knockdown. TNIK and TRAF2 were silenced in the human 
leukemia cell line SD-1 (BCR/ABL+) using transduction-ready viral par-
ticles for gene silencing (Santa Cruz Biotechnology Inc.). Briefly, 5 × 104 
SD-1 cells were transduced overnight at 37°C and 5% CO2 with 2 × 105 
infectious units of virus of shTNIK lentiviral particles or the respective 
control scrambled RNA lentiviral particles (Santa Cruz Biotechnology 
Inc.) in the presence of 5 μg/ml polybrene (Sigma-Aldrich) according to 
the manufacturer’s instructions. After 18 hours, medium was removed and 
cells were cultured in medium supplemented with 2.5 μg/ml puromycin to 
select for stable expression of shTNIK or scrambled RNA.
Immunohistochemistry. BM biopsy slides were immunohistochemically 
stained using an automated immunostainer (Benchmark XT). Briefly, for 
single stainings, slides were deparaffinized, pretreated with CC1 Buffer, 
and incubated with anti-human CD27 (clone 137B4, dilution 1:40; Novo-
castra) for 120 minutes at room temperature. Ab was detected with iView 
Universal DAB kit (brown, Ventana). For double stainings, slides were 
deparaffinized, pretreated with CC1, and incubated first with CD34 (clone 
QBEnd/10 dilution, as provided by manufacturer; Ventana) for 60 minutes 
at room temperature and detected with iView Universal DAB kit (brown). 
Afterwards, slides were stained with CD27 for 120 minutes at room tem-
perature and detected with iView Universal DAB Kit (red). Images were 
captured on an Eclipse E800 microscope with a DXM-1200 camera and 
analyzed using NIS Elements BR 3.0 software (Nikon Instruments).
Immunoprecipitation and Western blot analysis. SD-1 cells were lysed in ice-
cold radioimmunoprecipitation buffer (20 mM Tris-HCl, pH 7.4, 1% Triton 
X-100, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA containing a mixture of 
protease inhibitors; Roche) for 30 minutes at 4°C, followed by centrifuga-
tion at 14,000 g for 15 minutes at 4°C. 50 μg of cell lysate was precleared 
by adding 20 μl of Protein A/G Plus agarose beads and subsequently incu-
bated with rabbit anti-TRAF2 (clone: H-249; Santa Cruz Biotechnology 
Inc.) overnight at 4°C with gentle tumbling. 20 μl of agarose beads was 
added to the lysate for 2 hours at 4°C with gentle tumbling. The agarose 
beads were washed 3 times with ice-cold wash buffer (5 mM Tris-HCl, pH 
7.4, 20 mM NaCl, and 0.5% Triton X-100) and resuspended in 20 μl of 2× 
sample buffer, followed by elution through boiling.
Proteins were separated on a 4%–20% gradient SDS-PAGE gel (Bio-Rad), 
blotted onto a polyvinylidene difluoride membrane (Sigma-Aldrich), and 
stained with rabbit α-TRAF2 (clone H-249; Santa Cruz Biotechnology Inc.) 
or mouse α-TNIK (clone: 53; Santa Cruz Biotechnology Inc.) overnight at 
4°C. Subsequently, blots were incubated for 1 hour with donkey α-rabbit 
peroxidase IgG or sheep α-mouse peroxidase IgG (Amersham) and devel-
oped by enhanced chemiluminescence (Thermo Scientific).
Statistics. Statistical analysis was performed using GraphPad Prism 5.0 
(GraphPad Software). Data are represented as mean ± SEM. The Shapiro-
Wilk test was used to determine whether the data meet the assumption of 
normality. Data were analyzed using 1-way ANOVA and Tukey’s multiple 
comparison test, Student’s t test (2-tailed), 1-sample t test or 2-way ANOVA, 
and Bonferroni’s post-hoc test (P value shows interaction). Significance of 
differences in Kaplan-Meier survival curves was determined using the log-
rank test (2-tailed). P < 0.05 was considered significant.
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